grant
A novel role for EZH2 in A-to-I RNA editing in prostate cancer
Organization NORTHWESTERN UNIVERSITYLocation CHICAGO, UNITED STATESPosted 5 Feb 2024Deadline 31 Jan 2029
NIHUS FederalResearch GrantFY2026AdenosineAdenosine AminohydrolaseAffectAreaB lymphoma Mo MLV insertionBMI1BMI1 geneBenignBiological MarkersBiotechBiotechnologyCancer GenesCancer PatientCancer-Promoting GeneCancerousCancersCellular ExpansionCellular GrowthChIP SequencingChIP-seqChIPseqClinicalCombined Modality TherapyComplexDNADNA MethylationDNA mutationDataData SetDeoxyribonucleic AcidDevelopmentDrugsEC 2.1.1EnhancersEnzyme GeneEnzymesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpithelial CellsEpithelium of Human Prostate GlandEventFunctional RNAFutureGEM modelGEMM modelGene ExpressionGene InactivationGene SilencingGeneHomologGeneralized GrowthGenesGeneticGenetic ChangeGenetic defectGenetic mutationGenetically Engineered MouseGrowthHistone-Lysine MethyltransferaseHistone-Lysine N-MethyltransferaseHistonesHomologHomologous GeneHomologueImmune PrecipitationImmunoblot AnalysisImmunoprecipitationIn VitroInosineInvadedInvestigationL-LysineLysineMalignant CellMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMedicationMessenger RNAMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic Prostate CancerMetastatic TumorMethyltransferaseMicroRNAsModificationMultimodal TherapyMultimodal TreatmentMutationNeoplasm MetastasisNon-Polyadenylated RNANoncoding RNANontranslated RNAOncogenesOncogenicOutcomePDX modelPatient derived xenograftPatientsPharmaceutical AgentPharmaceutical PreparationsPharmaceuticalsPharmacologic SubstancePharmacological SubstancePlayPolycombPropertyProstateProstate CAProstate CancerProstate Carcinoma MetastaticProstate GlandProstate carcinomaProstate malignancyProstatic EpitheliumProstatic GlandProstatic carcinomaProtein Lysine MethyltransferaseProtein Methylase IIIProtein Methyltransferase IIIProteinsRNARNA EditingRNA Gene ProductsRNA SeqRNA SplicingRNA StabilityRNA methylationRNA sequencingRNA, Messenger, EditingRNAseqRegulationRelapseReportingResearch DesignResistance developmentResistant developmentRibonucleic AcidRoleSamplingSecondary NeoplasmSecondary TumorSiteSolidSolid NeoplasmSolid TumorSplicingStudy TypeTCGATOP2TOP2ATOP2A geneTP2ATestingThe Cancer Genome AtlasTherapeuticTimeTissue GrowthTranscriptTranscription RepressorTranscriptional RepressorTransforming GenesTranslationsTreatment EfficacyUntranslated RNAVariantVariationWorkadenosine deaminaseadvanced prostate cancerbio-markersbiologic markerbiomarkercancer cellcancer initiationcancer metastasiscancer typecarcinoma prostatic cancercell growthchromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingcombination therapycombined modality treatmentcombined treatmentdemethylationdesigndesigningdevelop therapydeveloping resistancedevelopmentaldrug/agentepigenetic regulationepigeneticallygain of functiongenetic repressorgenetically engineered mouse modelgenetically engineered murine modelgenome mutationhistone H3 methyltransferasehistone methylasehistone methyltransferasehistone modificationin vivo Modelinhibitorinsightintervention developmentintervention efficacyknock-downknockdownmRNAmalignancymenmethylasemiRNAmigrationmulti-modal therapymulti-modal treatmentmutantneoplasm/cancernew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnoncodingnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetontogenypatient derived xenograft modelpharmaceuticalprostate cancer cellprostate cancer progressionprostate tumor cellresistance to therapyresistant to therapysocial rolestudy designtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic efficacytherapeutic resistancetherapeutic targettherapy developmenttherapy efficacytherapy resistanttranscriptional silencingtranscriptome sequencingtranscriptomic sequencingtranslationtransmethylasetreatment developmenttreatment resistancetumortumor cell metastasistumor growth
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Abstract
Prostate cancer is one of the most common cancers among men, and although it can successfully be
treated in some men, others develop resistance to therapies and can relapse. Thus, it is prudent to discover
new therapeutic targets and develop therapeutic strategies that utilize already developed therapies to expedite
the development of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click